DEF: Pulse Biosciences Sets 2026 Annual Meeting Date

Pulse Biosciences announces its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to elect directors and ratify auditor appointments.

Summary

• Pulse Biosciences, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 11, 2026, at 11:00 a.m. Eastern Time.
• Stockholders of record as of April 28, 2026, are eligible to vote.
• The meeting agenda includes the election of seven directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026, and other business.
• Voting can be done by mail, telephone, or internet, with a deadline of June 10, 2026, at 11:59 p.m. Eastern Time.
• The company has fixed April 28, 2026, as the record date for determining stockholders entitled to vote.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to routine corporate governance and meeting logistics rather than operational or financial performance.

Positives

• The company is holding its annual meeting, indicating ongoing operations and governance processes.
• The virtual format aims to increase stockholder participation.
• Clear deadlines and voting instructions are provided for stockholders.
• The company is seeking to ratify its independent auditor, suggesting a commitment to financial transparency.

Negatives

• The filing does not contain financial performance data, making it difficult to assess the company's operational health.
• The company's Audit Committee was non-compliant with Nasdaq listing rules for a period in 2025 due to having only two independent directors, though it believes it has since regained compliance.

Risks

• The company's Audit Committee was non-compliant with Nasdaq listing rules for a period in 2025 due to having only two independent directors, though it believes it has since regained compliance.

Future Outlook

The filing primarily concerns the upcoming annual meeting and does not contain specific forward-looking financial guidance. However, it outlines the process for stockholder proposals for the 2027 annual meeting and director nomination procedures.

Management Comments

• "YOUR VOTE IS IMPORTANT."
• "Whether or not you plan to attend the virtual Annual Meeting, we request that you submit your vote via the Internet, telephone or mail."
• "Thank you for your continued support of Pulse Biosciences."

Industry Context

StockSavvy.ai notes that this filing is a standard proxy statement for an annual meeting, a common occurrence for publicly traded companies. The focus on director elections and auditor ratification aligns with typical corporate governance practices in the biotechnology sector.

Management Changes

Corporate Governance

Related Party Transactions

• Robert W. Duggan, the Company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered in the 2024 Rights Offering, contributing $60 million in gross proceeds.
• Mr. Danahy (former Chief Commercial Officer) and Dr. Zanganeh also participated in the 2024 Rights Offering.
• Robert W. Duggan and Mahkam Zanganeh have registration rights agreements for their shares.
• Mr. Duggan and Dr. Zanganeh are married, and their beneficial ownership of each other's securities may be deemed to exist, though they disclaim voting or investment power over the other's holdings.

Stakeholder Impact

• Stockholders: The meeting provides an opportunity for stockholders to vote on director elections and auditor ratification, influencing corporate governance.
• Management and Employees: The election of directors and ongoing governance processes impact management's strategic direction and operational oversight.
• Auditors: The ratification of Deloitte & Touche LLP confirms their continued role in auditing the company's financial statements.

Next Steps

• Stockholders are encouraged to vote by June 10, 2026.
• The company will hold its Annual Meeting on June 11, 2026.
• Final results of the Annual Meeting will be published in a Form 8-K.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic updates that would warrant a buy or sell recommendation. It focuses on governance matters, making 'hold' the most appropriate recommendation based solely on this document.

Keywords

Pulse Biosciences, DEF 14A, Proxy Statement, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, Virtual Meeting